Assessment off-label prescribing in dermatology;Evaluation des prescriptions hors AMM en dermatologie

Annales de Dermatologie et de Venereologie

Volumn 130, Issue 5, 2003, Pages 507-510

  Picard, D ^b   Carvalho, P ^b   Bonnavia, C ^b   Louin, L ^b   Josset, V ^b   Lauret, Ph ^b   Joly, P ^a  

^a HÔPITAL CHARLES NICOLLE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; METHOTREXATE; THALIDOMIDE;

ANALYTIC METHOD; ARTICLE; DATA ANALYSIS; DRUG INDICATION; DRUG LABELING; DRUG USE; EVIDENCE BASED MEDICINE; FRANCE; HOSPITAL DEPARTMENT; HUMAN; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; PATIENT COUNSELING; PHYSICIAN; PRESCRIPTION; QUANTITATIVE ANALYSIS; RECORDING; SKIN ALLERGY; SKIN DISEASE; SKIN INFLAMMATION; SYMPTOMATOLOGY; TREATMENT INDICATION;

DECISION MAKING; DERMATOLOGY; DRUG LABELING; DRUG THERAPY; FRANCE; HEALTH CARE SURVEYS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG;

EID: 0038007279     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Erickson SH, Bergman JJ, Schneeweiss R, Cherkin DC. The use of drugs for unlabeled indications. JAMA 1980;243:1543-6.
2. Avenel S, Bomkratz A, Dassieu G, Janaud JC, Danan C. The incidence of prescriptions without marketing product license in a neonatal intensive care unit. Arch Pediatr 2000;7:143-7.
3. Chalumeau M, Treluyer JM, Salanave B, Assathiany R, Cheron G, Crocheton N et al. Off label and unlicensed drug use among French office based paediatricians. Arch Dis Child 2000;83:502-5.
4. Sugarman JH, Fleicher AB, Feldman SR. Off-label prescribing in the treatment of dermatologic disease. J Am Acad Dermatol 2002;47:217-23.
5. Conroy S, Choonara I, Impicciatore P, Mohn A, Amell H, Rane A et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. BMJ 2000;320:79-82.
6. Pandolfini C, Impicciatore P, Provasi D, Rocchi F, Campi R, Bonati M. Off-label use of drugs in Italy: a prospective, observational and multicentre study. Acta Paediatrica 1991;3:339-47.
7. T'Jong GW, Eland IA, Sturkenboom M, Van Den Anker JN, Stricker BH. Unlicensed and off label prescription of drugs to children: population based cohort study. BMJ 2002;324:1313-4.
8. Bucheler R, Schwab M, Morike K, Kalchthaler B, Mohr H, Schroder H et al. Off label prescribing to children in primary care in Germany: retrospective cohort study. BMJ 2002;324:1311-2.
9. T'Jong GW, Vulto AG, De Hoog M, Schimmel KJ, Tibboel D, Van Den Anker. A Survey of the use of off-label and unlicensed drugs in a Dutch children's hospital. Pediatrics 2001;108:1089-93.
10. Abeni D, Girardelli CR, Masini C, Aprea R, Melchi CF, Puddu P et al. What proportion of dermatological patients receive evidence-based treatment? Arch Dermatol 2001;137:771-6.
11. Stern SR. Drug promotion for an unlabeled indication-The case of topical tretinoin. N Engl J Med 1994;331:1348-9.
12. Li VW, Jaffe MP, Li WW, Haynes HA. « Off-label » dermatologic therapies: usage, risks and mechanisms. Arch Dermatol 1998;134:1149-54.
13. Torres A. The use of Food and Drug Administration-Approved medications for unlabeled (off-label) uses. Arch Dermatol 1994;130:32-6.